Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. The company was founded in 2010 and is headquartered in Ankara, Turkey.
Turk Ilac ve Serum Sanayi AS (TRILC) - Total Assets
Latest total assets as of September 2025: TL6.12 Billion TRY
Based on the latest financial reports, Turk Ilac ve Serum Sanayi AS (TRILC) holds total assets worth TL6.12 Billion TRY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Turk Ilac ve Serum Sanayi AS - Total Assets Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Turk Ilac ve Serum Sanayi AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Turk Ilac ve Serum Sanayi AS's total assets of TL6.12 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0.2% |
| Accounts Receivable | TL1.21 Billion | 30.2% |
| Inventory | TL431.63 Million | 10.8% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL6.45 Million | 0.2% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turk Ilac ve Serum Sanayi AS's current assets represent 52.1% of total assets in 2024, an increase from 50.7% in 2018.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2024, down from 3.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 30.2% of total assets.
Turk Ilac ve Serum Sanayi AS Competitors by Total Assets
Key competitors of Turk Ilac ve Serum Sanayi AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Turk Ilac ve Serum Sanayi AS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Turk Ilac ve Serum Sanayi AS generates 0.64x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Turk Ilac ve Serum Sanayi AS generates $ 1.81 in net profit.
Turk Ilac ve Serum Sanayi AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 2.51 | 1.80 |
| Quick Ratio | 0.91 | 1.97 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL502.55 Million | TL 1.21 Billion | TL 151.61 Million |
Turk Ilac ve Serum Sanayi AS - Advanced Valuation Insights
This section examines the relationship between Turk Ilac ve Serum Sanayi AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 41.7% |
| Total Assets | TL3.99 Billion |
| Market Capitalization | $34.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Turk Ilac ve Serum Sanayi AS's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Turk Ilac ve Serum Sanayi AS's assets grew by 41.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Turk Ilac ve Serum Sanayi AS (2018–2024)
The table below shows the annual total assets of Turk Ilac ve Serum Sanayi AS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL3.99 Billion | +41.69% |
| 2023-12-31 | TL2.82 Billion | +169.95% |
| 2022-12-31 | TL1.04 Billion | +68.57% |
| 2021-12-31 | TL619.53 Million | +55.22% |
| 2020-12-31 | TL399.12 Million | +49.42% |
| 2019-12-31 | TL267.12 Million | +40.70% |
| 2018-12-31 | TL189.85 Million | -- |